ProPhase Labs (PRPH) announced it is in M&A related discussions not connected to a crypto treasury strategy. These discussions, if successful, could potentially recognize the underlying value of ProPhase at multiples of its current share price. The Company believes meaningful value drivers, including the $50M Crown Medical collections initiative, commercialization of the BE-Smart Esophageal Cancer Test, and the now-profitable, restructured Nebula Genomics subsidiary, remain significantly undervalued by the market. Achieving quorum and voting in favor of the current proxy proposals is essential to maintaining NASDAQ compliance and enabling the Company to move forward with these strategic initiatives. ProPhase anticipates updating shareholders in the near future.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRPH:
- ProPhase Labs urges shareholders to vote ‘FOR’ all proposed resolutions
- ProPhase Labs Delays Q3 Filing Amid Reorganization
- ProPhase Labs announces publication of BE-Smart Esophageal Cancer study
- ProPhase Labs engages RedChip to lead investor relations efforts
- ProPhase Labs announces study validating BE-Smart cancer test